Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.3 USD | -1.55% | -7.81% | -13.06% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.43B |
---|---|---|---|---|---|
Net income 2024 * | -234M | Net income 2025 * | -270M | EV / Sales 2024 * | - |
Net cash position 2024 * | 725M | Net cash position 2025 * | 476M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.98
x | P/E ratio 2025 * |
-4.7
x | Employees | 59 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.59% |
Latest transcript on Akero Therapeutics, Inc.
1 day | -1.55% | ||
1 week | -7.81% | ||
Current month | +2.06% | ||
1 month | -6.54% | ||
3 months | -6.67% | ||
6 months | +36.15% | ||
Current year | -13.06% |
Managers | Title | Age | Since |
---|---|---|---|
Jonathan Young
FOU | Founder | 54 | 17-03-31 |
Timothy Rolph
FOU | Founder | 70 | 17-03-31 |
Andrew Cheng
CEO | Chief Executive Officer | 57 | 18-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Seth Harrison
BRD | Director/Board Member | 63 | 16-12-31 |
Jane Henderson
BRD | Director/Board Member | 58 | 19-04-22 |
Mark Iwicki
CHM | Chairman | 57 | 18-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.12% | 234 M€ | +3.34% | - | |
0.10% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 20.3 | -1.55% | 610,023 |
24-05-13 | 20.62 | +4.94% | 567,628 |
24-05-10 | 19.65 | -5.53% | 567,401 |
24-05-09 | 20.8 | -1.05% | 414,291 |
24-05-08 | 21.02 | -4.54% | 581,020 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.06% | 1.43B | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- AKRO Stock